MID-VOLUME · SEX-BALANCED
erythromycin Side Effects
erythromycin (also sold as E-Mycin, Ery-Tab) sits MID-VOLUME #245 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 70% of sex-coded reports are female (11,428 F / 4,853 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 18,237
- FAERS reports
FDA Adverse Event Reporting System extract for erythromycin. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
erythromycin reporting skew - 70% of sex-coded reports are female (11,428 F / 4,853 M). Volume band MID-VOLUME #245 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for erythromycin (E-Mycin) (18,237 reports). Signature SEX-BALANCED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2003–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
DRUG HYPERSENSITIVITY leads 4,088 of 18,237 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (3,566 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,606 reports, 8.8%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 277 |
| PNEUMONIA | 242 |
| DIARRHOEA | 227 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 226 |
| CONFUSIONAL STATE | 225 |
| DYSPNOEA | 218 |
| BREAST CANCER STAGE III | 194 |
| VOMITING | 194 |
| DIZZINESS | 191 |
| BURSITIS | 188 |
| ANXIETY | 186 |
| ABDOMINAL PAIN UPPER | 182 |
| PYREXIA | 182 |
| ASTHENIA | 181 |
| INSOMNIA | 181 |
| DUODENAL ULCER PERFORATION | 179 |
| CONDITION AGGRAVATED | 178 |
| HYPERTENSION | 177 |
| C-REACTIVE PROTEIN ABNORMAL | 176 |
| MOBILITY DECREASED | 173 |
Reactions in Hospitalization Reports
Hospitalization mid-share (4,825, 26.5%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| VOMITING | 601 |
| DIARRHOEA | 578 |
| NAUSEA | 554 |
| DYSPNOEA | 548 |
| PNEUMONIA | 495 |
| FATIGUE | 492 |
| DIZZINESS | 477 |
| PYREXIA | 465 |
| HEADACHE | 440 |
| PAIN | 427 |
| DRUG HYPERSENSITIVITY | 397 |
| MALAISE | 394 |
| ASTHENIA | 385 |
| ARTHRALGIA | 384 |
| WEIGHT DECREASED | 363 |
| ABDOMINAL PAIN | 357 |
| RASH | 352 |
| ANXIETY | 351 |
How to read erythromycin FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 18,237 voluntary reports linked to erythromycin (E-Mycin, Ery-Tab), 2003-2025. Death is listed on 1,606 (8.8%). Hospitalization appears on 4,825 (26.5%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 70% of sex-coded reports are female (11,428 F / 4,853 M).
Read with erythromycin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 18,159 FAERS cases (Δ 78 lighter vs erythromycin); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 18,056 FAERS cases (Δ 181 lighter vs erythromycin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 17,976 FAERS cases (Δ 261 lighter vs erythromycin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 17,969 FAERS cases (Δ 268 lighter vs erythromycin); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 53.3 pp vs erythromycin's DEATH-HEAVY): CASELOAD · HOSP-MID.
erythromycin stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.